Global Non-coding RNA Assays Market
Global Non-coding RNA Assays Market

Non-coding RNA Assays Comprehensive Study by Type (Infrastructural non coding RNA, Regulatory non coding RNA), End-User (Laboratories, Research Centers, Others), Size (Small, Medium, Large, Others) Players and Region - Global Market Outlook to 2026

Non-coding RNA Assays Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 209 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Non-coding RNA Assays?
An RNA molecule that is not translated into a protein is known as a non-coding RNA (ncRNA). An RNA gene is the DNA sequence from which a functional non-coding RNA is transcribed. Transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), as well as short RNAs including microRNAs, siRNAs, piRNAs, snoRNAs, snRNAs, exRNAs, scaRNAs, and long ncRNAs like Xist and HOTAIR, are abundant and functionally significant. The amount of non-coding DNA found in different species varies substantially. Only a small percentage of the genome is responsible for coding proteins, but a growing percentage of the genome is being discovered to have regulatory activities. As predicted in the 1960s, when there is a lot of non-coding DNA, a lot of it appears to have no biological role. Since then, this non-functional section has been dubbed "junk DNA" in a contentious manner.

The market study is broken down by Type (Infrastructural non coding RNA and Regulatory non coding RNA) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Non-coding RNA Assays market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Springer Nature Limited (United Kingdom), Applied Microarrays Inc. (United States), C D Genomics (United States), RELX Group (United Kingdom), MilliporeSigma (United States), QIAGEN (Germany), Agilent Technologies, Inc. (United States), Danaher Corporation (United States), Eppendorf SE (Germany) and Thermo Fisher Scientific Company (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Non-coding RNA Assays market by Type, Application and Region.

On the basis of geography, the market of Non-coding RNA Assays has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Laboratories will boost the Non-coding RNA Assays market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Size , the sub-segment i.e. Small will boost the Non-coding RNA Assays market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • Innovation of New Techniques

Market Drivers
  • Rising Government Initiatives to Promote Life Science Research Projects

Opportunities
  • Rising Focus on Biomarker Discovery

Restraints
  • High Cost of Non-Coding RNA Assay

Challenges
  • Lack of Researchers in Developing Countries


Key Target Audience
Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Springer Nature Limited (United Kingdom), Applied Microarrays Inc. (United States), C D Genomics (United States), RELX Group (United Kingdom), MilliporeSigma (United States), QIAGEN (Germany), Agilent Technologies, Inc. (United States), Danaher Corporation (United States), Eppendorf SE (Germany) and Thermo Fisher Scientific Company (United States) etc.

2. Can we have customized study for Non-coding RNA Assays Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Non-coding RNA Assays Market by 2026?
Analysts at AMA estimates Non-coding RNA Assays Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Type
  • Infrastructural non coding RNA
  • Regulatory non coding RNA
By End-User
  • Laboratories
  • Research Centers
  • Others

By Size
  • Small
  • Medium
  • Large
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Government Initiatives to Promote Life Science Research Projects
    • 3.3. Market Challenges
      • 3.3.1. Lack of Researchers in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Innovation of New Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Non-coding RNA Assays, by Type, End-User, Size and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Non-coding RNA Assays (Value)
      • 5.2.1. Global Non-coding RNA Assays by: Type (Value)
        • 5.2.1.1. Infrastructural non coding RNA
        • 5.2.1.2. Regulatory non coding RNA
      • 5.2.2. Global Non-coding RNA Assays by: End-User (Value)
        • 5.2.2.1. Laboratories
        • 5.2.2.2. Research Centers
        • 5.2.2.3. Others
      • 5.2.3. Global Non-coding RNA Assays Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Non-coding RNA Assays: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Springer Nature Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Applied Microarrays Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. C D Genomics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. RELX Group (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MilliporeSigma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QIAGEN (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Agilent Technologies, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Danaher Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eppendorf SE (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Thermo Fisher Scientific Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Non-coding RNA Assays Sale, by Type, End-User, Size and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Non-coding RNA Assays (Value)
      • 7.2.1. Global Non-coding RNA Assays by: Type (Value)
        • 7.2.1.1. Infrastructural non coding RNA
        • 7.2.1.2. Regulatory non coding RNA
      • 7.2.2. Global Non-coding RNA Assays by: End-User (Value)
        • 7.2.2.1. Laboratories
        • 7.2.2.2. Research Centers
        • 7.2.2.3. Others
      • 7.2.3. Global Non-coding RNA Assays Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Non-coding RNA Assays: by Type(USD Million)
  • Table 2. Non-coding RNA Assays Infrastructural non coding RNA , by Region USD Million (2015-2020)
  • Table 3. Non-coding RNA Assays Regulatory non coding RNA , by Region USD Million (2015-2020)
  • Table 4. Non-coding RNA Assays: by End-User(USD Million)
  • Table 5. Non-coding RNA Assays Laboratories , by Region USD Million (2015-2020)
  • Table 6. Non-coding RNA Assays Research Centers , by Region USD Million (2015-2020)
  • Table 7. Non-coding RNA Assays Others , by Region USD Million (2015-2020)
  • Table 8. South America Non-coding RNA Assays, by Country USD Million (2015-2020)
  • Table 9. South America Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 10. South America Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 11. South America Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 12. Brazil Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 13. Brazil Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 14. Brazil Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 15. Argentina Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 16. Argentina Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 17. Argentina Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 18. Rest of South America Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 19. Rest of South America Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 20. Rest of South America Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 21. Asia Pacific Non-coding RNA Assays, by Country USD Million (2015-2020)
  • Table 22. Asia Pacific Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 23. Asia Pacific Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 24. Asia Pacific Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 25. China Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 26. China Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 27. China Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 28. Japan Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 29. Japan Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 30. Japan Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 31. India Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 32. India Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 33. India Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 34. South Korea Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 35. South Korea Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 36. South Korea Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 37. Taiwan Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 38. Taiwan Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 39. Taiwan Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 40. Australia Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 41. Australia Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 42. Australia Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 43. Rest of Asia-Pacific Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 44. Rest of Asia-Pacific Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 46. Europe Non-coding RNA Assays, by Country USD Million (2015-2020)
  • Table 47. Europe Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 48. Europe Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 49. Europe Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 50. Germany Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 51. Germany Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 52. Germany Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 53. France Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 54. France Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 55. France Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 56. Italy Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 57. Italy Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 58. Italy Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 59. United Kingdom Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 60. United Kingdom Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 61. United Kingdom Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 62. Netherlands Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 63. Netherlands Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 64. Netherlands Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 65. Rest of Europe Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 66. Rest of Europe Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 67. Rest of Europe Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 68. MEA Non-coding RNA Assays, by Country USD Million (2015-2020)
  • Table 69. MEA Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 70. MEA Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 71. MEA Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 72. Middle East Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 73. Middle East Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 74. Middle East Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 75. Africa Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 76. Africa Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 77. Africa Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 78. North America Non-coding RNA Assays, by Country USD Million (2015-2020)
  • Table 79. North America Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 80. North America Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 81. North America Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 82. United States Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 83. United States Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 84. United States Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 85. Canada Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 86. Canada Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 87. Canada Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 88. Mexico Non-coding RNA Assays, by Type USD Million (2015-2020)
  • Table 89. Mexico Non-coding RNA Assays, by End-User USD Million (2015-2020)
  • Table 90. Mexico Non-coding RNA Assays, by Size USD Million (2015-2020)
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Non-coding RNA Assays: by Type(USD Million)
  • Table 102. Non-coding RNA Assays Infrastructural non coding RNA , by Region USD Million (2021-2026)
  • Table 103. Non-coding RNA Assays Regulatory non coding RNA , by Region USD Million (2021-2026)
  • Table 104. Non-coding RNA Assays: by End-User(USD Million)
  • Table 105. Non-coding RNA Assays Laboratories , by Region USD Million (2021-2026)
  • Table 106. Non-coding RNA Assays Research Centers , by Region USD Million (2021-2026)
  • Table 107. Non-coding RNA Assays Others , by Region USD Million (2021-2026)
  • Table 108. South America Non-coding RNA Assays, by Country USD Million (2021-2026)
  • Table 109. South America Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 110. South America Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 111. South America Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 112. Brazil Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 113. Brazil Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 114. Brazil Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 115. Argentina Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 116. Argentina Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 117. Argentina Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 118. Rest of South America Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 119. Rest of South America Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 120. Rest of South America Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 121. Asia Pacific Non-coding RNA Assays, by Country USD Million (2021-2026)
  • Table 122. Asia Pacific Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 123. Asia Pacific Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 124. Asia Pacific Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 125. China Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 126. China Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 127. China Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 128. Japan Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 129. Japan Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 130. Japan Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 131. India Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 132. India Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 133. India Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 134. South Korea Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 135. South Korea Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 136. South Korea Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 137. Taiwan Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 138. Taiwan Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 139. Taiwan Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 140. Australia Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 141. Australia Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 142. Australia Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 143. Rest of Asia-Pacific Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 144. Rest of Asia-Pacific Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 145. Rest of Asia-Pacific Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 146. Europe Non-coding RNA Assays, by Country USD Million (2021-2026)
  • Table 147. Europe Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 148. Europe Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 149. Europe Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 150. Germany Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 151. Germany Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 152. Germany Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 153. France Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 154. France Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 155. France Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 156. Italy Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 157. Italy Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 158. Italy Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 159. United Kingdom Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 160. United Kingdom Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 161. United Kingdom Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 162. Netherlands Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 163. Netherlands Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 164. Netherlands Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 165. Rest of Europe Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 166. Rest of Europe Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 167. Rest of Europe Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 168. MEA Non-coding RNA Assays, by Country USD Million (2021-2026)
  • Table 169. MEA Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 170. MEA Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 171. MEA Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 172. Middle East Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 173. Middle East Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 174. Middle East Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 175. Africa Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 176. Africa Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 177. Africa Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 178. North America Non-coding RNA Assays, by Country USD Million (2021-2026)
  • Table 179. North America Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 180. North America Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 181. North America Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 182. United States Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 183. United States Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 184. United States Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 185. Canada Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 186. Canada Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 187. Canada Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 188. Mexico Non-coding RNA Assays, by Type USD Million (2021-2026)
  • Table 189. Mexico Non-coding RNA Assays, by End-User USD Million (2021-2026)
  • Table 190. Mexico Non-coding RNA Assays, by Size USD Million (2021-2026)
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Non-coding RNA Assays: by Type USD Million (2015-2020)
  • Figure 5. Global Non-coding RNA Assays: by End-User USD Million (2015-2020)
  • Figure 6. South America Non-coding RNA Assays Share (%), by Country
  • Figure 7. Asia Pacific Non-coding RNA Assays Share (%), by Country
  • Figure 8. Europe Non-coding RNA Assays Share (%), by Country
  • Figure 9. MEA Non-coding RNA Assays Share (%), by Country
  • Figure 10. North America Non-coding RNA Assays Share (%), by Country
  • Figure 11. Global Non-coding RNA Assays share by Players 2020 (%)
  • Figure 12. Global Non-coding RNA Assays share by Players (Top 3) 2020(%)
  • Figure 13. Global Non-coding RNA Assays share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Springer Nature Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Springer Nature Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 17. Applied Microarrays Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Applied Microarrays Inc. (United States) Revenue: by Geography 2020
  • Figure 19. C D Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 20. C D Genomics (United States) Revenue: by Geography 2020
  • Figure 21. RELX Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. RELX Group (United Kingdom) Revenue: by Geography 2020
  • Figure 23. MilliporeSigma (United States) Revenue, Net Income and Gross profit
  • Figure 24. MilliporeSigma (United States) Revenue: by Geography 2020
  • Figure 25. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 26. QIAGEN (Germany) Revenue: by Geography 2020
  • Figure 27. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Agilent Technologies, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 31. Eppendorf SE (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Eppendorf SE (Germany) Revenue: by Geography 2020
  • Figure 33. Thermo Fisher Scientific Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Thermo Fisher Scientific Company (United States) Revenue: by Geography 2020
  • Figure 35. Global Non-coding RNA Assays: by Type USD Million (2021-2026)
  • Figure 36. Global Non-coding RNA Assays: by End-User USD Million (2021-2026)
  • Figure 37. South America Non-coding RNA Assays Share (%), by Country
  • Figure 38. Asia Pacific Non-coding RNA Assays Share (%), by Country
  • Figure 39. Europe Non-coding RNA Assays Share (%), by Country
  • Figure 40. MEA Non-coding RNA Assays Share (%), by Country
  • Figure 41. North America Non-coding RNA Assays Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Springer Nature Limited (United Kingdom)
  • Applied Microarrays Inc. (United States)
  • C D Genomics (United States)
  • RELX Group (United Kingdom)
  • MilliporeSigma (United States)
  • QIAGEN (Germany)
  • Agilent Technologies, Inc. (United States)
  • Danaher Corporation (United States)
  • Eppendorf SE (Germany)
  • Thermo Fisher Scientific Company (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation